Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 105

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 105
---
 December 31, 2024. Due to these factors, the Gross Margin % increased significantly from (87.15%) for the year ended December 31, 2023 to 37.78% for the year ended December 31, 2024. Other Operating Revenues

| Consolidated Statements of Operations Data: |     | For the Year Ended 
 December 31,       
 2024               |        |     | 2023 |   |     | $ Change |        |     | % Change |     |
|:--------------------------------------------|:----|:-------------------|-------:|:----|:-----|:--|:----|:---------|-------:|:----|:---------|:----|
| Research Revenues                           |     | $                  | 73,771 |     | $    | - |     | $        | 73,771 |     |          | N/A |

The research revenues earned by us were $73,771 for the year ended December 31, 2024, as compared to $0 for the year ended December 31, 2023. Our research revenues for the year ended December 31, 2024 primarily relate to research revenues earned from the Australian Tax Authority for research expenses conducted in Australia, and we earned $55,395 during the year ended December 31, 2024 ($0 during the year ended December 31, 2023). We did not earn research revenues from the Australian Tax Authority in 2023 due to the cancellation of our COVID-19 trial, after which we made the decision not to file for the research rebate. In 2024, we also began to recognize research revenues related to the new USAMMDA contract we were awarded in July 2024 to facilitate commercial validation of a new bottle and replacement blister packaging of Arakoda. Operating Expenses

|                                     | Consolidated Statements of Operations Data: | For the Year Ended 
 December           
 31,                |       2024 |     |   |      2023 |     |   |  $ Change |     |     | % Change |   |
|:------------------------------------|:--------------------------------------------|:-------------------|-----------:|:----|:--|----------:|:----|:--|----------:|:----|:----|---------:|:--|
| Research and Development            |                                             | $                  |  4,986,526 |     | $ |   691,770